- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03099811
Financial Incentives to Reduce Pediatric Tobacco Smoke Exposures
19. november 2018 oppdatert av: Johns Hopkins University
Contingency Management for Controlling Secondhand Smoke Exposures Among Asthmatic Children
Secondhand smoke exposure (SHSe) is one of the most common and potentially modifiable environmental triggers for asthma.
Financial incentivization may serve as an effective modality to reduce SHSe among pediatric asthmatics with potential down-stream benefits on improved asthma control and subsequent reduced healthcare utilization.
This study plans on testing the feasibility and effectiveness of financial incentives to decrease SHSe, derived from primary caregivers and a member of their social network, of children with persistent asthma.
Studieoversikt
Status
Fullført
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
The impact of continued cigarette usage is profoundly felt not only upon the primary smoker, but also among children where SHSe is linked with asthma exacerbations.
Children with caregivers who are active smokers are more likely to utilize acute healthcare resources and miss more days of school due to asthma symptoms.
Issues of pediatric smoke exposure are notably higher among low-income populations.
This particular group has a greater amount of financial strain that increases their desire to cease smoking but is among the least successful at accomplishing this task.
Aggressive marketing campaigns by cigarette companies have specifically targeted the urban poor but similar techniques by public health officials, though on a much diminished scale, have yet to completely counter the hold that this addictive product has on members of lower socioeconomic status.
One approach that has demonstrated efficacy in reducing smoking in resistant populations emphasizes financial incentives.
Incentives may provide a substitute for the gratification derived from nicotine if they are properly structured.
This proposal applies a contingency management schema among caregivers of pediatric asthmatics and a member of their caregiver's social network - both of whom are likely major contributors to the child's total secondhand smoke exposure.
A pilot two-arm randomized-control trial will be employed over a 6-month time interval.The study population will consist of the primary caregiver and a selected member of their social network, both of who are known active smokers, and contemplating smoking cessation; both individuals spend time (either indoors or outdoors) with the asthmatic child.
We will recruit 50 caregiver-child-social network triads among a population of children diagnosed with uncontrolled, persistent asthma and routinely exposed to high levels of SHSe.
Caregivers and members of their social network who are both active smokers will be randomized to receive standard smoking cessation strategies (n=25 triads) with or without financial incentives (n=25 triads).
SHSe will be measured directly using salivary cotinine levels from children and home air nicotine levels.
Caregiver and social network member smoking behaviors will be measured by nicotine biomarkers; both test results will be the basis for incentive payments.
Asthma control will be evaluated using validated questionnaires and review of the participant's electronic health record.
Studietype
Intervensjonell
Registrering (Faktiske)
147
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
Maryland
-
Baltimore, Maryland, Forente stater, 21287
- Johns Hopkins Hospital
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
2 år til 12 år (Barn)
Tar imot friske frivillige
Ja
Kjønn som er kvalifisert for studier
Alle
Beskrivelse
Inclusion Criteria:
- Primary caregiver aged greater than 18 years who is an active smoker.
- Child aged 2-12 years of age who meets clinical criteria for persistent asthma and has nicotine biomarker levels consistent with secondhand smoke exposure
- Designated social network member who is an active smoker
- Residence in Baltimore City
Exclusion Criteria:
- Child has current diagnosis of another major pulmonary disease or other significant medical co-morbidity
- Use of electronic cigarettes (e-cigarettes) by the adult-enrolled participants
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Helsetjenesteforskning
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Intervention: Financial incentives + Smoking cessation program
Caregiver and a social network member will receive financial incentives, in additional to enrollment in a state-sponsored smoking cessation program, based on nicotine biomarker measurements.
|
The caregiver and designated social network member can each receive monthly financial incentives over the 6 month time interval.
Additional monthly incentives will be received at 3- and 6-months if the participant's previous two monthly biomarker levels were below the lower-limit cutoff.
Andre navn:
Participants who wish to quit smoking will be referred upon study recruitment to the smoking cessation program that is provided at no-cost by the Maryland Department of Health and Mental Hygiene (DMMH).
The DMMH provides standard counseling and nicotine replacement pharmacotherapies for clients and is offered online or at six health centers throughout Baltimore City.
Andre navn:
|
|
Annen: Intervention: Smoking cessation program
Caregiver and a social network member will be enrolled in a state-sponsored smoking cessation program.
|
Participants who wish to quit smoking will be referred upon study recruitment to the smoking cessation program that is provided at no-cost by the Maryland Department of Health and Mental Hygiene (DMMH).
The DMMH provides standard counseling and nicotine replacement pharmacotherapies for clients and is offered online or at six health centers throughout Baltimore City.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Pediatric secondhand smoke exposures
Tidsramme: 6 months
|
Monthly measurement of pediatric secondhand smoke exposures.
Secondhand smoke exposures will be measured using salivary cotinine levels.
|
6 months
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Nicotine biomarkers
Tidsramme: 6 months
|
Monthly measurements of nicotine biomarkers to objectively assess tobacco usage.
This will serve as the trigger for monthly financial incentives for those allocated to the intervention group.
|
6 months
|
|
Air nicotine
Tidsramme: 6 months
|
Home air nicotine levels will be measured to assess if tobacco-derived indoor air pollutant levels will decline with the intervention.
Air nicotine levels will be acquired through passive air samplers and measured using gas chromatography.
|
6 months
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Etterforskere
- Hovedetterforsker: Mandeep S Jassal, MD, Johns Hopkins University
Publikasjoner og nyttige lenker
Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. juni 2017
Primær fullføring (Faktiske)
1. november 2018
Studiet fullført (Faktiske)
1. november 2018
Datoer for studieregistrering
Først innsendt
17. mars 2017
Først innsendt som oppfylte QC-kriteriene
28. mars 2017
Først lagt ut (Faktiske)
4. april 2017
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
20. november 2018
Siste oppdatering sendt inn som oppfylte QC-kriteriene
19. november 2018
Sist bekreftet
1. november 2018
Mer informasjon
Begreper knyttet til denne studien
Andre studie-ID-numre
- IRB00064875
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .